{"id":57549,"date":"2023-06-08T13:04:54","date_gmt":"2023-06-08T11:04:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/"},"modified":"2023-06-08T13:04:54","modified_gmt":"2023-06-08T11:04:54","slug":"acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/","title":{"rendered":"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics"},"content":{"rendered":"
\n

FOSTER CITY, Calif.–(BUSINESS WIRE)–Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx\u00ae Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis.<\/p>\n

<\/a><\/p>\n

\nNanoString\u2019s GeoMx DSP is a powerful spatial biology platform that enables researchers to uncover intricate interactions between cells and identify the driving signaling pathways in multicellular systems. By spatially profiling whole transcriptome and high-plex protein expression in tissue samples, it provides invaluable insights into the cellular microenvironment, revealing the complex interplay between different cell types and the molecular mechanisms that contribute to disease progression. Acrobat Genomics, an innovative startup within the Illumina Accelerator Program specializing in gene editing technologies, will join forces with NanoString to receive a GeoMx DSP Technology Access Program grant. The grant was facilitated by the Illumina Accelerator, which brings together innovative genomics start-up companies with NanoString to form valuable partnerships.<\/p>\n

\nNick Hughes, the co-founder\/CEO of Acrobat Genomics, commented on the potential of gene editing technology, “Gene editing holds immense promise for the treatment of genetic diseases. By precisely targeting the molecular markers of IPF, we aim to develop targeted therapies that can significantly improve the lives of patients.”<\/p>\n

\nDr. Tushar Desai, professor of medicine at Stanford Medicine, also shared his thoughts on the collaboration, “Our goal is to discover signaling between cells within pathological foci and between the foci and surrounding lung tissue. By comparing different regions in IPF samples and non-IPF (normal) lung tissue, we can better understand the development of the disease and identify critical signaling interactions. This work could provide new insights and therapies for interstitial lung diseases.”<\/p>\n

\n\u201cInterstitial lung disease is a devastating diagnosis. The lungs become damaged by increased scarring and there is currently no cure for ILD,\u201d said Brad Gray, President and CEO of NanoString. \u201cThere are more than 200 different types of ILD, and we hope that our powerful portfolio of spatial technologies can help advance our understanding of ILD, and potentially lead to new treatments to help improve patient outcomes and quality of life.\u201d<\/p>\n

\nThe collaboration with NanoString, Illumina Accelerator, and Stanford Medicine presents Acrobat Genomics with a unique opportunity to harness the power of GeoMx DSP technology, expediting the discovery of new drug targets for interstitial lung diseases.<\/p>\n

\nAbout Acrobat Genomics<\/b><\/p>\n

\nAcrobat Genomics is a biotechnology startup focused on developing precise gene editing therapeutics using its protein engineering platform. The company’s proprietary platform technology allows for precise editing of disease-causing mutations, aiming to provide targeted therapies for those with limited treatment options. For more information, visit https:\/\/www.acrobatgenomics.com\/<\/a>.<\/p>\n

\nAbout NanoString<\/b><\/p>\n

\nNanoString Technologies, a leader in spatial biology<\/a>, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx\u00ae Digital Spatial Profiler, cited in approximately 200 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx\u2122 Spatial Molecular Imager is an FFPE-compatible, single-cell imaging<\/a> platform powered by spatial multi omics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx\u2122 Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter\u00ae Analysis System, cited in approximately 7,200 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, please visit www.nanostring.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nDoug Farrell
\n
Vice President, Investor Relations & Corporate Communications
\n
DFarrell@NanoString.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FOSTER CITY, Calif.–(BUSINESS WIRE)–Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx\u00ae Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57549","6":"format-standard","7":"category-industry"},"yoast_head":"\nAcrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FOSTER CITY, Calif.–(BUSINESS WIRE)–Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx\u00ae Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-08T11:04:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230608005342\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics\",\"datePublished\":\"2023-06-08T11:04:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/\"},\"wordCount\":665,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230608005342\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/\",\"name\":\"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230608005342\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\",\"datePublished\":\"2023-06-08T11:04:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230608005342\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230608005342\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics - Pharma Trend","og_description":"FOSTER CITY, Calif.–(BUSINESS WIRE)–Acrobat Genomics, NanoString Technologies, Inc. (NASDAQ:NSTG), and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new drug targets for gene editing-based therapeutics using GeoMx\u00ae Digital Spatial Profiling (DSP) technology. This collaboration aims to improve treatment options for patients suffering from interstitial lung diseases, such as idiopathic pulmonary fibrosis. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/","og_site_name":"Pharma Trend","article_published_time":"2023-06-08T11:04:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230608005342\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics","datePublished":"2023-06-08T11:04:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/"},"wordCount":665,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230608005342\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/","url":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/","name":"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230608005342\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","datePublished":"2023-06-08T11:04:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230608005342\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230608005342\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/acrobat-genomics-nanostring-and-illumina-accelerator-collaborate-with-stanford-medicine-to-discover-new-drug-targets-for-gene-editing-based-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57549"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57549\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}